MedPacto "MOU for Joint Antibody Drug Research with Theragen Etex and JinScript"

[Asia Economy Reporter Hyunseok Yoo] MedPacto, a biomarker-based innovative drug development company, announced on the 26th that it has signed a memorandum of understanding (MOU) for joint research and development and cooperation in the field of antibody therapeutics with its affiliate Theragen Etex and global contract development and manufacturing organization (CDMO) company GenScript.

GenScript, headquartered in New Jersey, USA, and listed on the Hong Kong market, is a global bio company providing various CDMO services such as research sample production and gene and cell therapy production. According to this agreement, the three companies will strategically partner in the development process and related research and service projects, including the discovery, manufacturing, and clinical trials of antibody therapeutic candidates.

MedPacto plans to promote the development of new pipeline candidates, and Theragen Etex will jointly develop antibody therapeutics related to intractable cancers and chronic immune diseases based on newly discovered targets through genomic analysis.

Seongjin Kim, CEO of MedPacto, explained, “We have secured numerous biomarkers showing effective characteristics for the onset and treatment through genomic analysis of cancer patients, and the development of innovative antibody drugs based on these biomarkers will be fully activated starting from this agreement.”

Byunghwan Ryu, CEO of Theragen Etex, stated, “By combining GenScript’s antibody drug technology with our genomic analysis, new drug development, and pharmaceutical production experience, we will enhance our capabilities in the antibody drug field and promote global new drug development in various areas.”

Brian Min, Head of GenScript’s CDMO division, added, “We expect MedPacto and Theragen Etex to be excellent partners in the field of antibody drug development due to their outstanding basic R&D capabilities and innovativeness, and we will provide our best support.”

Meanwhile, GenScript has subsidiaries including GenScript ProBio, which handles CDMO, and Legend Biotech, a developer of immune oncology CAR-T cell therapies listed on the US stock market. It has a sales network in over 100 countries worldwide through offices located in the USA, China, Hong Kong, Japan, Singapore, the Netherlands, and Ireland.

The signing ceremony was held on the 25th at MedPacto’s headquarters in Seocho-gu, Seoul.